Cargando…
Fecal Calprotectin as a Diagnostic and Prognostic Biomarker for Gastrointestinal Graft Versus Host Disease: A Systematic Review of Literature
The current practice for diagnosing graft versus host disease (GVHD) includes clinical or endoscopic evaluation of the patient. Clinical diagnosis is limited by an overlapping symptomatic spectrum with infectious causes, a common scenario in the post-transplant setting where an invasive procedure, s...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488450/ https://www.ncbi.nlm.nih.gov/pubmed/31058026 http://dx.doi.org/10.7759/cureus.4143 |
_version_ | 1783414644994473984 |
---|---|
author | Malik, Mustafa N Rafae, Abdul Durer, Ceren Durer, Seren Anwer, Faiz |
author_facet | Malik, Mustafa N Rafae, Abdul Durer, Ceren Durer, Seren Anwer, Faiz |
author_sort | Malik, Mustafa N |
collection | PubMed |
description | The current practice for diagnosing graft versus host disease (GVHD) includes clinical or endoscopic evaluation of the patient. Clinical diagnosis is limited by an overlapping symptomatic spectrum with infectious causes, a common scenario in the post-transplant setting where an invasive procedure, such as endoscopy, is often impractical. We, therefore, evaluated the role of fecal calprotectin as a diagnostic as well as a prognostic biomarker for gastrointestinal GVHD (GI-GVHD) occurrence and severity in the post-hematopoietic transplant population. Following Prisma guidelines, we performed a systematic search of articles published after 2004 using the PubMed, Embase, Cochrane Library, and Web of Science databases. After a detailed screening, 10 studies involving a total of 494 patients were included. In the cohorts comparing median fecal calprotectin (mFC) level in GI-GVHD vs. non-GI-GVHD patients, the results indicated an increase in the mFC level in patients with GI-GVHD when compared to non-GI-GVHD patients. Similarly, an increase in the mFC level was seen in accordance with the severity of the disease. Moreover, corticosteroid-resistant patients had a higher mFC level as compared to corticosteroid-sensitive patients. Our study indicates that the mFC level can be used for diagnosing as well as predicting the treatment response to GI-GVHD. However, future randomized prospective trials involving larger populations are needed to further explore its significance. |
format | Online Article Text |
id | pubmed-6488450 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-64884502019-05-05 Fecal Calprotectin as a Diagnostic and Prognostic Biomarker for Gastrointestinal Graft Versus Host Disease: A Systematic Review of Literature Malik, Mustafa N Rafae, Abdul Durer, Ceren Durer, Seren Anwer, Faiz Cureus Infectious Disease The current practice for diagnosing graft versus host disease (GVHD) includes clinical or endoscopic evaluation of the patient. Clinical diagnosis is limited by an overlapping symptomatic spectrum with infectious causes, a common scenario in the post-transplant setting where an invasive procedure, such as endoscopy, is often impractical. We, therefore, evaluated the role of fecal calprotectin as a diagnostic as well as a prognostic biomarker for gastrointestinal GVHD (GI-GVHD) occurrence and severity in the post-hematopoietic transplant population. Following Prisma guidelines, we performed a systematic search of articles published after 2004 using the PubMed, Embase, Cochrane Library, and Web of Science databases. After a detailed screening, 10 studies involving a total of 494 patients were included. In the cohorts comparing median fecal calprotectin (mFC) level in GI-GVHD vs. non-GI-GVHD patients, the results indicated an increase in the mFC level in patients with GI-GVHD when compared to non-GI-GVHD patients. Similarly, an increase in the mFC level was seen in accordance with the severity of the disease. Moreover, corticosteroid-resistant patients had a higher mFC level as compared to corticosteroid-sensitive patients. Our study indicates that the mFC level can be used for diagnosing as well as predicting the treatment response to GI-GVHD. However, future randomized prospective trials involving larger populations are needed to further explore its significance. Cureus 2019-02-27 /pmc/articles/PMC6488450/ /pubmed/31058026 http://dx.doi.org/10.7759/cureus.4143 Text en Copyright © 2019, Malik et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Infectious Disease Malik, Mustafa N Rafae, Abdul Durer, Ceren Durer, Seren Anwer, Faiz Fecal Calprotectin as a Diagnostic and Prognostic Biomarker for Gastrointestinal Graft Versus Host Disease: A Systematic Review of Literature |
title | Fecal Calprotectin as a Diagnostic and Prognostic Biomarker for Gastrointestinal Graft Versus Host Disease: A Systematic Review of Literature |
title_full | Fecal Calprotectin as a Diagnostic and Prognostic Biomarker for Gastrointestinal Graft Versus Host Disease: A Systematic Review of Literature |
title_fullStr | Fecal Calprotectin as a Diagnostic and Prognostic Biomarker for Gastrointestinal Graft Versus Host Disease: A Systematic Review of Literature |
title_full_unstemmed | Fecal Calprotectin as a Diagnostic and Prognostic Biomarker for Gastrointestinal Graft Versus Host Disease: A Systematic Review of Literature |
title_short | Fecal Calprotectin as a Diagnostic and Prognostic Biomarker for Gastrointestinal Graft Versus Host Disease: A Systematic Review of Literature |
title_sort | fecal calprotectin as a diagnostic and prognostic biomarker for gastrointestinal graft versus host disease: a systematic review of literature |
topic | Infectious Disease |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488450/ https://www.ncbi.nlm.nih.gov/pubmed/31058026 http://dx.doi.org/10.7759/cureus.4143 |
work_keys_str_mv | AT malikmustafan fecalcalprotectinasadiagnosticandprognosticbiomarkerforgastrointestinalgraftversushostdiseaseasystematicreviewofliterature AT rafaeabdul fecalcalprotectinasadiagnosticandprognosticbiomarkerforgastrointestinalgraftversushostdiseaseasystematicreviewofliterature AT durerceren fecalcalprotectinasadiagnosticandprognosticbiomarkerforgastrointestinalgraftversushostdiseaseasystematicreviewofliterature AT durerseren fecalcalprotectinasadiagnosticandprognosticbiomarkerforgastrointestinalgraftversushostdiseaseasystematicreviewofliterature AT anwerfaiz fecalcalprotectinasadiagnosticandprognosticbiomarkerforgastrointestinalgraftversushostdiseaseasystematicreviewofliterature |